Clinical Trial Update: An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema [Phase 2]

View source ↗

Summary

Phase 2 extension study of Donidalorsen (IONIS-PKK-LRx) in participants with hereditary angioedema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Donidalorsen (antisense oligonucleotide targeting prekallikrein)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hereditary Angioedema | Phase 2 | Status: COMPLETED